Retina Eye Center

02/19/2026

Meet Dr. Oksana Maria Demediuk, MD, FACS - a board-certified ophthalmologist and fellowship-trained retina specialist with decades of experience treating complex retinal conditions. Dr. Demediuk brings deep clinical expertise, academic rigor, and a strong research background to her work. She has been proudly serving the Augusta area since 1995. Learn more: https://brnw.ch/21x05Ri

02/17/2026

Seeing flashes of light or floating specks in your vision? These are common as we age and often result from changes in the gel inside your eye. But sudden increases in flashes or floaters can signal a more serious retinal issue, so it’s important to get checked by an eye doctor right away. Learn more: https://brnw.ch/21x01ZC

02/12/2026

Protecting your retinal health starts with prevention. Regular exercise, a nutrient-rich diet, quitting smoking, and managing conditions like diabetes and high blood pressure can help reduce your risk of vision loss. Learn more: https://brnw.ch/21wZTqW

02/10/2026

Ocugen has shared encouraging phase 1 trial results for OCU410ST, a gene therapy for Stargardt disease. The treatment slowed lesion growth and showed early signs of improving vision in patients. A larger phase 2/3 trial is now underway, with FDA approval targeted for 2027. Learn more: https://brnw.ch/21wZOw0

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

02/05/2026

Having trouble seeing in the dark? It could be more than just aging eyes. Your retina plays a key role in night vision, and certain conditions like AMD, diabetic retinopathy, or retinitis pigmentosa can impair it. Learn what changes to watch for and when to see a specialist in our latest blog: https://brnw.ch/21wZGZ4

02/03/2026

February is Age-Related Macular Degeneration and Low Vision Awareness Month - a time to spotlight the leading cause of vision loss in adults over 50. AMD affects the retina and can make everyday tasks like reading or seeing faces more difficult. Early diagnosis and regular eye exams are key to protecting your vision. Learn more: https://brnw.ch/21wZCTB

01/29/2026

Ocular Therapeutix is moving forward with plans to seek FDA approval for AXPAXLI, a potential new treatment for wet age-related macular degeneration (wet AMD). Backed by encouraging results from a phase 3 clinical trial, AXPAXLI could offer a new option for patients by helping maintain vision with fewer injections. Learn more: https://brnw.ch/21wZuGu

Ocular Therapeutix accelerates NDA plans for AXPAXLI, targeting wet AMD treatment, following promising phase 3 trial results.

01/27/2026

Kiora Pharmaceuticals has received a new patent for KIO-104, a potential non-steroidal treatment for retinal inflammation. Unlike traditional steroids, KIO-104 targets inflammation at the cellular level and is being tested in a Phase 2 trial for conditions like non-infectious uveitis and diabetic macular edema. This innovation may offer new hope for patients with inflammatory eye diseases. Learn more: https://brnw.ch/21wZrr6

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.

01/22/2026

Macular holes and macular puckers affect the macula, the part of the retina responsible for sharp central vision. They can cause blurred or distorted vision and make everyday tasks like reading or recognizing faces more difficult. Many cases only need monitoring, but surgery is an option when vision loss begins to impact quality of life. Learn more: https://brnw.ch/21wZjww

01/20/2026

Ocular Therapeutix has started a phase 3 clinical trial to test a new treatment called AXPAXLI for non-proliferative diabetic retinopathy (NPDR), a common cause of vision loss in people with diabetes. This one-time, long-lasting treatment could reduce the need for frequent eye injections and help more patients protect their sight. Learn more: https://brnw.ch/21wZf3i

HELIOS-3 is a phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

01/15/2026

Your retina plays a vital role in how you see by sending images to your brain. At The Retina Eye Center, we use advanced technology to diagnose and treat a wide range of retinal, macular, and vitreous conditions with personalized care focused on protecting your vision. Learn more: https://brnw.ch/21wZ7vY

01/13/2026

A new treatment for wet age-related macular degeneration may be one step closer. Ocular Therapeutix plans to move faster toward FDA review of AXPAXLI after positive results from a large clinical trial showed it helped maintain vision when compared to current standard treatments. Learn more about this potential advancement and what it could mean for patients with wet AMD: https://brnw.ch/21wZ3OK

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.